**Supplemental Table 5**. Treatment-Emergent Extrapyramidal Symptoms Determined by Rating Scale Scores in the All-Treated Set.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Scale | PBO | ASN2.5 mg bid | ASN5 mg bid | OLZ15 mg qd |
| AIMS severity abnormal movements (item 8) score ≥2nan (%) | 1012 (2.0) | 971 (1.0) | 113 0 (0.0) | 450 (0.0) |
| BARS global score ≥2nan (%) | 983 (3.1) | 941 (1.1) | 1133 (2.7) | 421 (2.4) |
| SARS mean total score >3nan (%) | 903 (3.3) | 872 (2.3) | 1073 (2.8) | 423 (7.1) |
| AIMS, Abnormal Involuntary Movement Scale; ASN, asenapine; BARS, Barnes Akathisia Rating Scale; bid, twice daily; OLZ, olanzapine; PBO, placebo; qd, once daily; SARS, Simpson-Angus Rating Scale.Treatment-emergent extrapyramidal symptom by rating scale scores are measured after baseline and up to 7 days after study medication stop date.aRestricted to patients who had the following at baseline: an AIMS severity of abnormal movements (item 8) score <2, a BARS global score <2, or a SARS total score ≤3, respectively. |